Department of Medical Elementology and Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, India.
Department of Medical Elementology and Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, India.
Biochem Pharmacol. 2020 Oct;180:114184. doi: 10.1016/j.bcp.2020.114184. Epub 2020 Jul 30.
COVID-19, the greatest public health emergency of the 21st century, has affected 215 countries and territories around the world resulting in 15,151,738 confirmed cases and 621,121 deaths. The outbreak has continued at breakneck pace despite stringent public health measures, ravaging the global economy and causing profound human casualties. Vaccination is currently the best bet for the prevention of COVID-19. Still, in its absence, there has been considerable interest in repurposing existing therapeutic agents to reduce the severity of the illness and ease the burden on the already strained healthcare systems. This review outlines the current evidence regarding proposed treatments- experimental or repurposed, for COVID-19, and gives an insight into the clinical trial landscape for drugs as well as vaccines.
新型冠状病毒肺炎(COVID-19)是 21 世纪最大的公共卫生突发事件,已影响全球 215 个国家和地区,确诊病例达 15151738 例,死亡 621121 例。尽管采取了严格的公共卫生措施,但疫情仍在迅速蔓延,重创全球经济,造成了巨大的人员伤亡。接种疫苗目前是预防 COVID-19 的最佳选择。然而,在没有疫苗的情况下,人们对重新利用现有的治疗药物以减轻疾病的严重程度并减轻已经紧张的医疗体系的负担产生了浓厚的兴趣。本综述概述了目前关于 COVID-19 的拟议治疗方法(实验性或重新利用性)的证据,并深入了解了药物和疫苗的临床试验情况。